Treatment strategies in myelodysplastic syndromes. Cancer Invest 2008 Mar;26(2):208-16
Date
02/09/2008Pubmed ID
18259954DOI
10.1080/07357900701788122Scopus ID
2-s2.0-38949120072 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Myelodysplastic syndromes (MDS) are a group of disorders characterized by progressive cytopenias and transformation to acute leukemia. Over the last four years, we have experienced a revolution in the treatment of MDS. Three drugs were approved in the U.S. Two of them, 5-azacitidine and 5-aza-2'-deoxycitidine, induce DNA hypomethylation. The third agent, lenalidomide, is a thalidomide analogue with significant activity in a subset of patients with low-risk MDS, anemia and chromosome 5 alterations. Several other agents are being evaluated in MDS. In this short review, we will summarize our current approach to the therapy of patients with MDS.
Author List
Atallah E, Garcia-Manero GAuthor
Ehab L. Atallah MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HumansMyelodysplastic Syndromes